NEW POSSIBILITIES OF THERAPY OF INTENSIVELY PRETREATED METASTATIC COLORECTAL CANCER PATIENTS
نویسندگان
چکیده
منابع مشابه
FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer.
BACKGROUND The combination of oxaliplatin, 5-fluorouracil (5FU) and leucovorin (LV) has shown to be active and safe as first- or second-line chemotherapy for metastatic colorectal cancer (MCC). PATIENTS AND METHODS The outcome of patients with MCC who had progressive disease after at least two lines of palliative chemotherapy and who were subsequently treated with oxaliplatin, 5FU and LV was ...
متن کاملGemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer.
BACKGROUND Patients with metastatic breast cancer (MBC) are increasingly exposed to anthracyclines and taxanes either during treatment of primary breast cancer or during initial therapy of metastatic disease. The combination of gemcitabine and carboplatin was therefore investigated as an anthracycline- and taxane-free treatment option. PATIENTS AND METHODS MBC patients previously treated with...
متن کاملMetastatic Colorectal Cancer: Lessons Learned, Future Possibilities.
Survival of patients with metastatic colorectal cancer has dramatically improved over the past 20 years, primarily because physicians have become adept at using the many regimens approved for this patient population. Future advances may come from understanding molecular subtypes, finding and treating new actionable mutations, and harnessing the immune system.
متن کاملTherapy for metastatic colorectal cancer.
Median overall survival of metastatic colorectal cancer patients treated with first- and second-line combination chemotherapy now extends to more than 20 months in some studies. Chemotherapy alone, particularly when oxaliplatin is included, may allow potentially curative resection of advanced disease. There is evidence that the addition of antibodies targeted against vascular endothelial growth...
متن کاملNew possibilities in chemotherapy for colorectal cancer.
Colorectal cancer is the second leading cause of cancer death. Approximately 26,000 new cases are diagnosed yearly in France, resulting in more than 10,000 deaths, and 5-year survival remains low, at 40%. This poor prognosis is partly due to the fact that, in 30% of cases, colorectal cancer is metastatic or at a locally advanced stage when discovered. Moreover, visceral metastases complicate th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medical Council
سال: 2016
ISSN: 2079-701X
DOI: 10.21518/2079-701x-2016-10-24-32